Viral vector and cell/gene therapy facilities can be less complicated and require fewer critical utilities when compared to pharmaceutical or biotech facilities. Such facilities frequently do not have specialized requirements such as low particulate levels or high-quality water systems as many processes are small-scale and enclosed. Viral vector facilities usually require multiple laboratories to perform assays and rooms to house controlled temperature units that require nothing more than adequate power and controlled classified environments. This webinar will discuss risk assessment and qualification that is phase-appropriate for your CGT operation.
Speaker: Moria Feighery-Ross, CQA, CMQ/OE, Senior Consultant at Pharmatech Associates
Visit our website: pharmatechasso...
Негізгі бет Cost Savings Related to Qualifying Cell and Gene Therapy Facilities
Пікірлер